TG Therapeutics Inc（TGTX）の財務TGTXTG Therapeutics Inc

TG Therapeutics, Inc. (TGTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Total product revenue, net, accounting for 98.2% of total sales, equivalent to $201.31M. Another important revenue stream is License, milestone, royalty and other revenue. Understanding this composition is critical for investors evaluating how TGTX navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, TG Therapeutics, Inc. maintains a gross margin of 82.86%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.02%, while the net margin is 3.24%. These profitability ratios, combined with a Return on Equity (ROE) of 100.28%, provide a clear picture of how effectively TGTX converts its operational activities into shareholder value.

In the context of the broader market, TGTX competes directly with industry leaders such as IBRX and SYRE. With a market capitalization of $7.46B, it holds a significant position in the sector. When comparing efficiency, TGTX's gross margin of 82.86% stands against IBRX's 99.42% and SYRE's N/A. Such benchmarking helps identify whether TG Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a total revenue of $240 million in Q2 2026, exceeding market expectations, and raised its full-year revenue guidance to approximately $950 million, reflecting strong sales performance of its product Briumvi.